AOLS:OTC-Aeolus Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.17M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD97.09B 30.68 18.52
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD96.88B 30.77 18.52
TKPHF Takeda Pharmaceutical Company ..

N/A

USD44.64B 11.73 0.07
ESALF Eisai Co. Ltd

N/A

USD20.64B 39.09 0.17
SGIOF Shionogi & Co. Ltd

N/A

USD20.48B 19.30 0.11
SGIOY Shionogi & Co. Ltd

N/A

USD20.48B 19.20 0.11
ESALY Eisai Co. Ltd

N/A

USD20.45B 38.68 0.17
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD18.44B 17.60 2.44
TEVJF Teva Pharmaceutical Industries..

N/A

USD10.91B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing AOLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -65.22% 17% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.22% 17% F 10% F
Trailing 12 Months  
Capital Gain -50.00% 22% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.00% 22% F 13% F
Trailing 5 Years  
Capital Gain -99.58% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.58% 3% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain 24.31% 55% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.31% 54% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 196.41% 34% F 23% F
Risk Adjusted Return 12.38% 45% F 31% F
Market Capitalization 0.17M 6% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.81 72% C- 73% C
Price / Cash Flow Ratio -0.05 32% F 58% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -186.43% 21% F 7% F
Return on Invested Capital -195.58% 9% F 4% F
Return on Assets -90.30% 15% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.57 15% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.